Perseus Proteomics, Inc.
TTSE:4882144.00
JPY
-3.00
(-2.04%)
ISIN
JP3836800007
Return %
Stock
S&P 500
1Y
-53.55
14.20
3Y
-66.74
81.12
5Y
-75.00
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Takuya Yokogawa
- Full Time Employees
- 35
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 30-1 Nihonbashi Hakozakicho Tokyo TY Japan 103-0015
- IPO Date
- Jun 22, 2021
- Website
- ppmx.com
- Similar Companies
- Business
- Perseus Proteomics Inc is a biotechnology company specializing in antibody drug discovery and development. Founded in 2007 and headquartered in Chuo-ku, Tokyo, the company operates primarily in the pharmaceutical and biotechnology sectors with a focus on therapeutic antibody development. Its core products include a pipeline of antibody therapeutics such as PPMX-T001, targeting glypican 3 on cancer cell membranes for hepatocarcinoma; PPMX-T002, an anticancer drug; and PPMX-T003, a therapeutic agent for adult T-cell leukemia. In addition, Perseus Proteomics provides antibody research support services including antibody generation and sequence analysis and sells a wide range of antibodies and reagents, notably monoclonal antibodies against various nuclear receptors and proteins. The company conducts drug discovery through preclinical and early clinical stages, typically progressing candidates through phase I/IIa trials before licensing out for late-stage development, receiving upfront fees, milestones, and royalties. Perseus Proteomics also serves academia and research institutions with antibody products and research reagents. Geographically, the company operates mainly in Japan but collaborates widely through partnerships and licensing agreements. Significant recent developments include a collaborative research agreement signed in October 2024 with UBE Corporation focusing on antibody-drug conjugates (ADCs), specifically the joint development of PPMX-T004 and broader exploratory ADC research leveraging proprietary ADC technologies. This partnership aims to optimize combinations of antibodies and drug/linker technologies to improve efficacy and safety profiles. In December 2025, Perseus Proteomics entered a joint research agreement with Eurus Therapeutics to explore new therapeutic applications of antibodies. These alliances highlight the company’s strategic expansion in advanced antibody drug modalities and collaborative innovation. The company maintains a strong focus on expanding its antibody drug pipeline and research capabilities through these strategic partnerships. Overall, Perseus Proteomics Inc develops and commercializes innovative therapeutic antibodies with a comprehensive product pipeline and research support services, supported by key strategic collaborations to advance antibody-drug conjugate technologies and novel therapeutic antibody discovery primarily within Japan and international research networks.